We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Lung Cancer

Journal Scan / Research · February 18, 2021

A Blood-Based Assay for Assessment of Tumor Mutational Burden in First-Line Metastatic NSCLC Treatment

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
A Blood-Based Assay for Assessment of Tumor Mutational Burden in First-Line Metastatic NSCLC Treatment: Results From the MYSTIC Study
Clin. Cancer Res 2020 Dec 22;[EPub Ahead of Print], H Si, M Kuziora, KJ Quinn, E Helman, J Ye, F Liu, U Scheuring, S Peters, NA Rizvi, P Brohawn, K Ranade, BW Higgs, KC Banks, VK Chand, R Raja

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading